Key outcomes from stakeholder workshops at a symposium to inform the development of an Australian national plan for rare diseases

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Molster, Caron ^a   Youngs, Leanne ^a   Hammond, Emma ^a   Dawkins, Hugh ^a,b,c  

^a DEPARTMENT OF HEALTH   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

National plan; Rare diseases; Stakeholder consultation

Indexed keywords

ARTICLE; AUSTRALIA; COOPERATION; EMPOWERMENT; FUNDING; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; POLITICS; RARE DISEASE; SOCIAL NETWORK; SOCIAL WORK; WORKSHOP;

AUSTRALIA; EDUCATION; HEALTH PLANNING; HUMANS; RARE DISEASES;

EID: 84864819821     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-50     Document Type: Article

References (47)

1. Access to and quality of health and social care for rare diseases: patients' and caregivers' experiences. Kodra Y, Morosini PR, Petrigliano R, Agazio E, Salerno P, Taruscio D, Annali di igiene: medicina preventiva e di comunit 2007 19 153 160
2. Empowerment of patients: lessons from the rare diseases community. Aymé S, Kole A, Groft S, Lancet 2008 9629 2048 2051 (Pubitemid 351802281)
3. Networking for rare diseases: Orphanate research initiatives and reference centres. Aymé S, Schmidtke J, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007 50 1477 1483 10.1007/s00103-007- 0381-9 18026888
4. Tackling the problem of rare diseases in public health: the Italian approach. Taruscio D, Ido M, Daina E, Schieppati A, Community Genet 2003 6 123 124 10.1159/000073009 14560074 (Pubitemid 37323451)
5. Tackling rare diseases at the European level: why do we need a harmonized framework? Taruscio D, Trama A, Stefanov R, Folia Med 2007 49 59 67
6. National plans and strategies on rare diseases in Europe. Taruscio D, Vittozzi L, Stefanov R, Adv Exp Med Biol 2010 686 475 491 10.1007/978-90-481- 9485-8-26 20824461
7. Rare diseases - avoiding misperceptions and establishing realities: the need for reliable epidemiological data. Groft S, Posada De La Paz M, Adv Exp Med Biol 2010 2010 3 14
8. Creating a European Union framework for actions in the field of rare diseases. Moliner AM, Adv Exp Med Biol 2010 686 457 473 10.1007/978-90-481-9485- 8-25 20824460
9. Awakening Australia to rare diseases: symposium report and preliminary outcomes. Dawkins H, Molster C, Youngs L, O'Leary P, Orphanet J Rare Dis 2011 6 57 10.1186/1750-1172-6-57 21849083
10. Call for a national plan for rare diseases. Jaffe A, Zurynski Y, Beville L, Elliott E, J Paediatr Child Health 2009 46 2 4 19943870
11. The common problem of rare disease in general practice. Knight A, Senior T, Medical Journal of Australia 2006 185 82 83 16842062 (Pubitemid 44164816)
12. International conferences on rare diseases: initiatives in commitment, patient care and connections. Knight AW, Taruscio D, Medical Journal of Australia 2007 187 74 76 17635086 (Pubitemid 47162350)
13. Rare Diseases Working Group convened by the Australian Pediatric Surveillance Unit. Improving outcomes for rare diseases in Australia, a national plan for rare diseases (not for public distribution)
14. Minister of Health and Social Protection, Secretary of State for Handicapped People, Minister of Research. French national plan for rare diseases 2005-2008. Ensuring equity in the access to diagnosis, treatment and provision of care 2004
15. Law of 11 February 2005 for equal rights and opportunities, participation and citizenship of people with disabilities (LOI n°2005-102 du 11 février 2005 pour l'égalité des droits et des chances, la participation et la citoyenneté des personnes handicapées) France 2005 2005 2102
16. European Commission. National plans or strategies for rare diseases 2011 http://ec.europa.eu/health/rare-diseases/national-plans/detailed/index-en.htm
17. Rare Diseases Task Force(Australian Pediatric Surveillance Unit), Task Force Rare Diseases National Plan draft 19 Jan 2009 2009
18. Blueprint for a deliberative public forum on biobanking policy: were theoretical principles achievable in practice? Molster C, Maxwell S, Youngs L, et al. Health Expect 2011 10.1111/j.1369-7625.2011.00701.x
19. Care for patients with ultra-rare disorders. Hennekam R, Eur J Med Genet 2011 54 220 224 10.1016/j.ejmg.2010.12.001 21147279
20. The National Organization for Rare Disorders (NORD): providing advocacy for people with rare disorders. Putkowski S, NASN Sch Nurse 2010 25 38 41 10.1177/1942602X09352796 20440954
21. The impact of parent advocacy groups, the Internet and social networking on rare diseases: the IDEA League and IDEA League United Kingdom example. Black A, Baker M, Epilepsia 2011 52 102 104 21463291
22. The use of the internet in data assimilation in rare diseases. Bedgood R, Sadursk R, Schade R, Digestive Diseases and Science 2007 52 307 312 10.1007/s10620-006-9213-2 (Pubitemid 46202797)
23. Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service. Stakisaitis D, Sopkiene I, Juskevicius J, Valuckas K, Baiardi P, Medicina (Kaunas) 2007 43 441 446
24. Patient registries: utility, validity and inference. Richesson R, Vehik K, Adv Exp Med Biol 2010 686 87 104 10.1007/978-90-481-9485-8-6 20824441
25. Rare childhood diseases: how should we respond? Zurynski Y, Leonard H, Elliott E, Arch Dis Child 2008 93 1071 1074 10.1136/adc.2007.134940 18684747
26. Why rare diseases are an important medical and social issue. Schiepatti A, Henter J, Darina E, Aperia A, Lancet 2008 371 2039 10.1016/S0140-6736(08) 60872-7 18555915 (Pubitemid 351799861)
27. Developing a national collaborative study system for rare genetic diseases. Watson M, Epstein C, Howell R, et al. Genet Med 2008 10 325 329 10.1097/GIM.0b013e31817b80fd 18496030 (Pubitemid 351770401)
28. Clinical research for rare disease: opportunities, challenges and solutions. Griggs R, Batshaw M, Dunkle M, et al. Mol Genet Metab 2009 96 20 26 10.1016/j.ymgme.2008.10.003 19013090
29. Aymé S, Rodwell C, Report on the state of the art of rare disease activities in Europe of the European Union Committee of Experts on Rare Diseases-Part I: overview of rare disease activities in Europe and key developments in 2010 2011 http://wwweucerdeu/upload/file/Reports/ 2011ReportStateofArtRDActivitiespdf
30. Overview of Rare Disease Activities in Europe & Key Developments in 2010. European Union Committee of Experts on Rare Diseases (EUCERD), Report on the State of the Art of Rare Disease Activities in Europe, Aymé S, Rodwell C, 2011
31. CEMARA an information system for rare diseases. Landais P, Messiaen C, Rath A, et al. Study health technology Information 2010 160 part1 481 485
32. International rare disease research consortium commits to agressive goals. Baxter K, Terry S, Genetic Testing and Molecular Markers 2011 15 7 8
33. Rare diseases social epidemiology: analysis of inequalities. Kole A, Faurisson F, Adv Exp Med Biol 2010 686 223 250 10.1007/978-90-481-9485-8-14 20824449
34. Huntington disease: families' experiences of healthcare services. Skirton H, Williams J, Jackson Barnette J, Pausen J, J Adv Nurs 2010 66 500 510 10.1111/j.1365-2648.2009.05217.x 20423385
35. Meeting the needs of parents around the time of diagnosis of disability among their children: evaluation of a novel program for information, support and liaison by key workers. Rahi J, Manaras I, Tuomainen H, Hundt G, Pediatrics 2004 114 477 482 10.1542/peds.2004-0240 15466074 (Pubitemid 41534571)
36. Battista RN, Blancquaert I, Laberge AM, van Schendel N, Leduc N, Genetics in health care: an overview of current and emerging models Genomics: Public Health 2011 1 12
37. From symptom onset to a diagnosis of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND): experiences of people with ALS/MND and family carers-a qualitative study. O'Brien M, Whitehead B, Jack B, Mitchell J, Amyotroph Lateral Scler 2011 12 97 104 10.3109/17482968.2010.546414 21208037
38. Diagnostic delay in sternocostoclavicular hyperostosis: impact on various aspects of quality of life. van der Kloot W, Chotkan S, Kaptein A, Hamdy N, Arthritis Care Res (Hoboken) 2010 62 251 257 10.1002/acr.20075
39. Measuring integrated care. Strandberg-Larsen M, Dan Med Bull 2011 58 4245 21299927
40. What are the current barriers to effective cancer care coordination?A qualitative study. Walsh J, Harrison J, Young J, Butow P, Solomon M, Masya L, BMC Health Serv Res 2010 10 132 10.1186/1472-6963-10-132 20482884
41. How did uncommon disorders become 'rare diseases'? History of a boundary object. Huyard C, Sociol Health Illn 2009 31 463 477 10.1111/j.1467-9566.2008. 01143.x 19397760
42. Fund Rare Diseases and Orphan Drugs. Recommendations and proposed measures for the Belgian Plan for Rare Diseases: Phase 1 Brussels: Belgium: Managed by the King Baudouin Foundation 2010
43. Taking the patients side: the ethics of pharmacogenetics. Hansson M, Personalized Medicine 2010 7 75 85 10.2217/pme.09.47
44. Orphan drug designation and pharmacogenomics: options and opportunities. Maher P, Haffner M, BioDrugs 2006 20 71 79 10.2165/00063030-200620020-00001 16626164
45. Maher P, ed Personalized Medicine: Pharmacogenomics of Rare and Monogenic Disorders in Pharmacogenomics and 2008
46. Report of an international survey of molecular genetic testing laboratories. McGovern M, Elles R, Beretta I, et al. Community Genet 2007 10 123 131 10.1159/000101753 17575456 (Pubitemid 46944287)
47. Le Henanff G. Tchernia G. French experience with rare diseases plans Orphanet Journal of Rare Disease 2010 5 157 10.1186/1750-1172-5-S1-O7